XML 44 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2017
Shareholders' Equity [Abstract]  
Schedule of Company's stock options plans
   Number of options  Weighted average exercise price  

Weighted average remaining contractual term

(in years)

  Aggregate intrinsic value 
              
 Outstanding as of January 1, 2017  624,437   10.47   3.55  $4,576 
 Granted  179,002   19.48         
 Exercised  (109,487)  8.13         
 Expired and forfeited  (14,400)  11.29         
                  
 Outstanding as of  December 31, 2017  679,552   13.20   3.35  $4,517 
                  
 Vested and expected to vest at December 31, 2017  679,552   13.20   3.35  $4,517 
                  
 Exercisable as of December 31, 2017  254,850   10.31   2.35  $2,431 
Schedule of stock options under 2013 share option plan
   

Options outstanding

at December 31, 2017

  

Options exercisable

at December 31, 2017

 
 Exercise price Number outstanding  Weighted average exercise price  Weighted average remaining contractual life  Number exercisable  Weighted average exercise price  Weighted average remaining contractual life 
 $    $  In years     $  In years 
                    
 2.71-3.90  25,000   3.21   0.95   25,000   3.21   0.95 
 5.35-8.60  47,800   6.87   1.58   47,800   6.87   1.58 
 10.49 – 14.52  427,750   11.87   3.15   182,050   12.19   2.74 
 18.90-19.85  179,002   19.48   4.62   -   -   - 
                          
    679,552           254,850         
Schedule of RSUs under the Company's 2013 share option plan

   Number of RSUs  

Weighted average remaining contractual term

(in years)

  Aggregate intrinsic value 
           
 Outstanding as of January 1, 2017  193,150   2.02  $3,438 
 Granted  105,428         
 Vested  (52,724)        
 Cancelled  (5,800)        
              
 Outstanding as of December 31, 2017  240,054   1.74  $4,765 
              
 Vested and expected to vest as of December 31, 2017   240,054   1.74  $4,765 
Summary of departmental allocation of share-based compensation charge
   Year ended December 31, 
   2017(*)  2016(*)  2015(*) 
           
 Cost of revenues $189  $118  $33 
 Research and development, net  473   625   529 
 Sales and marketing, net  499   199   380 
 General and administrative  1,055   1,529   467 
              
   $2,216  $2,471  $1,409 

 

(*)Including $1,335, $1,331 and $342 of compensation cost related to RSUs for the year ended December 31, 2017, 2016 and 2015, respectively.